PYC Therapeutics Ltd
ASX:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PYC Therapeutics Ltd
Total Receivables
PYC Therapeutics Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Receivables
AU$32.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
219%
|
CAGR 10-Years
74%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Receivables
$43.3m
|
CAGR 3-Years
104%
|
CAGR 5-Years
67%
|
CAGR 10-Years
19%
|
|
|
CSL Ltd
ASX:CSL
|
Total Receivables
$4.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Receivables
AU$32.3k
|
CAGR 3-Years
-71%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Receivables
AU$16.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
28%
|
CAGR 10-Years
23%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Receivables
AU$135.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's Total Receivables?
Total Receivables
32.6m
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's Total Receivables amounts to 32.6m AUD.
What is PYC Therapeutics Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
74%
Over the last year, the Total Receivables growth was 166%. The average annual Total Receivables growth rates for PYC Therapeutics Ltd have been 55% over the past three years , 219% over the past five years , and 74% over the past ten years .
